What is a stock summary page? Click here for an overview.
Business Description
Akums Drugs and Pharmaceuticals Ltd
ISIN : INE09XN01023
Compare
Compare
Traded in other countries / regions
544222.India IPO Date
2024-08-06Description
Akums Drugs and Pharmaceuticals Ltd a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services in India and overseas. Its services include formulation research and development (R&D), preparation and filing of regulatory dossiers in the Indian and Outside markets, and other testing services. It is also engaged in the manufacturing and sale of branded pharmaceutical formulations and active pharmaceutical ingredients (APIs). The operates in three segments: a) Contract Development and Manufacturing Operations (CDMO), b) Active Pharmaceutical Ingredient (API), and c) Branded and Generic formulations. Key revenue is generated from Contract Development and Manufacturing Operations (CDMO).
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.55 | |||||
| Equity-to-Asset | 0.66 | |||||
| Debt-to-Equity | 0.19 | |||||
| Debt-to-EBITDA | 1.82 | |||||
| Interest Coverage | 7.65 | |||||
| Piotroski F-Score | 8/9 | |||||
| Altman Z-Score | 4.3 | |||||
| Beneish M-Score | -2.98 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 14.3 | |||||
| 3-Year EBITDA Growth Rate | -19.3 | |||||
| 3-Year EPS without NRI Growth Rate | 14.1 | |||||
| 3-Year FCF Growth Rate | 57.5 | |||||
| 3-Year Book Growth Rate | -6.2 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 62.03 | |||||
| 9-Day RSI | 55.89 | |||||
| 14-Day RSI | 51.8 | |||||
| 3-1 Month Momentum % | -19.68 | |||||
| 6-1 Month Momentum % | -44.51 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.13 | |||||
| Quick Ratio | 1.59 | |||||
| Cash Ratio | 0.67 | |||||
| Days Inventory | 133.74 | |||||
| Days Sales Outstanding | 124.8 | |||||
| Days Payable | 118.3 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | 0.9 | |||||
| Shareholder Yield % | 2.31 |
Profitability Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 36.39 | |||||
| Operating Margin % | 7.85 | |||||
| Net Margin % | 3.32 | |||||
| FCF Margin % | 6.6 | |||||
| ROE % | 6.86 | |||||
| ROA % | 2.47 | |||||
| ROIC % | 5.13 | |||||
| 3-Year ROIIC % | -18.68 | |||||
| ROC (Joel Greenblatt) % | 7.64 | |||||
| ROCE % | 7.21 | |||||
| Years of Profitability over Past 10-Year | 3 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 77.05 | |||||
| PE Ratio without NRI | 49.74 | |||||
| PS Ratio | 2.61 | |||||
| PB Ratio | 2.63 | |||||
| Price-to-Tangible-Book | 2.63 | |||||
| Price-to-Free-Cash-Flow | 40.96 | |||||
| Price-to-Operating-Cash-Flow | 15.35 | |||||
| EV-to-EBIT | 40.07 | |||||
| EV-to-EBITDA | 24.52 | |||||
| EV-to-Revenue | 2.53 | |||||
| EV-to-FCF | 34.07 | |||||
| Price-to-Graham-Number | 1.56 | |||||
| Price-to-Net-Current-Asset-Value | 6.27 | |||||
| Earnings Yield (Greenblatt) % | 2.5 | |||||
| FCF Yield % | 2.5 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Akums Drugs and Pharmaceuticals Ltd Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ₹) | 28,292.07 | ||
| EPS (TTM) (₹) | 6.311 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | - | ||
| 14-Day RSI | 51.8 | ||
| 14-Day ATR (₹) | 27.545478 | ||
| 20-Day SMA (₹) | 472.59 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range (₹) | 407.4 - 1174.85 | ||
| Shares Outstanding (Mil) | 153.1 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 8 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Akums Drugs and Pharmaceuticals Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Akums Drugs and Pharmaceuticals Ltd Stock Events
| Event | Date | Price (₹) | ||
|---|---|---|---|---|
| No Event Data | ||||
Akums Drugs and Pharmaceuticals Ltd Frequently Asked Questions
What is Akums Drugs and Pharmaceuticals Ltd(BOM:544222)'s stock price today?
The current price of BOM:544222 is ₹486.25. The 52 week high of BOM:544222 is ₹1174.85 and 52 week low is ₹407.40.
When is next earnings date of Akums Drugs and Pharmaceuticals Ltd(BOM:544222)?
The next earnings date of Akums Drugs and Pharmaceuticals Ltd(BOM:544222) is .
Does Akums Drugs and Pharmaceuticals Ltd(BOM:544222) pay dividends? If so, how much?
Akums Drugs and Pharmaceuticals Ltd(BOM:544222) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers